Racial differences in potassium response to spironolactone in heart failure

Congest Heart Fail. 2006 Jul-Aug;12(4):200-5. doi: 10.1111/j.1527-5299.2006.05502.x.

Abstract

Evidence of racial differences in aldosterone concentrations and K+ disposition suggests that response to aldosterone antagonism might vary by race. The authors sought to determine whether K+ response to spironolactone differs between African Americans and Caucasians with heart failure. Heart failure patients of African-American (n = 34) or Caucasian (n = 17) race were started on spironolactone 12.5 mg/d, with up-titration as tolerated. Laboratory values and drug therapy were similar between racial groups at baseline. Spironolactone was titrated to a median dose of 25 mg/d in both groups. Neither concomitant medications nor serum creatinine changed significantly in either group during spironolactone dose titration. Median serum K+ concentrations increased by 0.5 mEq/L (range, -0.7 to 1.6 mEq/L) in Caucasians, but only 0.1 mEq/L (range, -0.8 to 0.9 mEq/L) in African Americans; p < 0.01. These data suggest that African Americans with heart failure may be less responsive to the renal effects of spironolactone.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Black or African American*
  • Female
  • Heart Failure* / blood
  • Heart Failure* / drug therapy
  • Heart Failure* / ethnology
  • Humans
  • Male
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists / pharmacology*
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Potassium / blood*
  • Spironolactone / pharmacology*
  • Spironolactone / therapeutic use
  • White People*

Substances

  • Mineralocorticoid Receptor Antagonists
  • Spironolactone
  • Potassium